Description
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC 50 and a K i of 1.5 nM and 11.9 nM, respectively TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer researchIC50& Target:IC50: 1.5 nM,Ki: 11.9 nM (BTK)